NYSE · LLY
Eli Lilly and Company
$1,433.15+$59.45 (+4.33%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
OTC · THMO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ThermoGenesis Holdings, Inc.’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$5.85. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ThermoGenesis Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ThermoGenesis Holdings, Inc., founded in 1986 and based in Rancho Cordova, California, is a global innovator specializing in automated systems for cell-banking, cell-processing, and cell-based therapeutic applications. The company's advanced solutions are available across the United States, China, the United Arab Emirates, Vietnam, and other international regions. Its product portfolio encompasses medical devices crucial for automated cell processing. For clinical bio-banking purposes, ThermoGenesis provides the AXP II Automated Cell Separation System, a fully closed system designed for isolating stem and progenitor cells from umbilical cord blood. Complementing this is the BioArchive Automated Cryopreservation System, a robotic, liquid nitrogen-controlled system for both freezing and long-term cryogenic storage of cord blood samples and cell therapeutic products used in clinical environments. In the realm of point-of-care applications, the company offers the XP Point-of-Care System, an automated, sterile, and closed platform that facilitates the rapid processing of autologous stem cells derived from peripheral blood or bone marrow aspirate directly within clinical settings such as surgical centers. Additionally, the PXP-1000 System is another automated, closed solution, engineered for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. For general laboratory use, ThermoGenesis provides its X-Series cell processing products, including X-Lab for cell isolation, the X-Wash System for efficient cell washing and reformulation, and X-Mini for high-efficiency, small-scale cell purification. Beyond its product offerings, the company also delivers contract development and manufacturing (CDMO) services specifically for cell and cell-based gene therapies. Its medical device products are marketed and sold through a network of independent distributors, as well as directly to end-user customers. The company, formerly known as Cesca Therapeutics Inc., officially adopted the name ThermoGenesis Holdings, Inc. in November 2019.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:05 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2023 | Aug 10, 2023 | -$0.91-9,200.0% vs estimate | $2.27M-50.59% vs estimate |
|---|
| Q1 2023 | May 15, 2023 | -$3.88-1,151.61% vs estimate | $2.57M-3.89% vs estimate |
|---|
| Q4 2022 | Mar 30, 2023 | $0.25+127.78% vs estimate | $2.70M-6.79% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,433.15+$59.45 (+4.33%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$2.68-$0.02 (-0.74%)
Edesa Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.81% below the high.
$1.72-$0.03 (-1.71%)
Vyome Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.78% below the high.
$0.39-$0.01 (-1.49%)
Bone Biologics Corporation’s quoted price sits in the lower half of its reported 52-week range, 83.75% below the high.
$0.58-$0.04 (-6.78%)
Valion Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.15% below the high.
$5.53-$0.25 (-4.33%)
Nuwellis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.64% below the high.
$0.00$0.00 (0.0%)
Baudax Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
BIMI International Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
